Cyrcadia, Inc. Prepares for iTBra™ Product Launch and Expands Strategic Operations to Asia

Cyrcadia, Inc.(CI) announced this week a strategic expansion to accelerate operations and market launch into Asia for early breast cancer monitoring. CI has entered into a License and Cooperation Agreement Cyrcadia Asia, Ltd. (CA), a newly formed company in Hong Kong which will serve as the base for the Asia market launch of CI’s proprietary iTBraTM technology expected to commence in late 2017 or early 2018 under the global CI brand of Cyrcadia Health. Under the License and Cooperation Agreement, Cyrcadia Asia has exclusive marketing rights to the iTBra technology and products in Asia. CA will assume and fund certain further product development and other activities with respect to the iTBra technology and products for the benefit of both CI and CA. The License and Cooperation Agreement also provides for certain other financial terms between the two parties intended to enable the launch of the technology and products in Asia. CI retains exclusive marketing rights to the United States, Mexico and Canada, with the marketing strategy for the iTBra technology and products in other countries to be further discussed by the parties. Having obtained U.S. FDA 510(k) Class II approval for its iTBra technology, CI has conducted clinical trials in the U.S. with its newly developed scalable product, which demonstrates greatly improved outcomes, beyond historical product results. CI’s predictive analytic artificial intelligence (AI) based technology now demonstrates 80%+ accuracy with a two-hour wear when compared with the original trials which required 48-hour wear and achieved 74% accuracy. CI and CA expect this greatly improved performance to support the use of the 510(k) approval to launch the technology and products...

Early Detection – Nedra

The opportunity of early detection and management of breast tissue abnormalities is a reality and has already made significant impacts in many lives. Nedra’s story is just one of those. Please take a moment to hear about the impact of the Cyrcadia Health technology in Nedra’s life, along with support and thoughts of the primary investigator of this particular study, Dr. Ronald...

First Warning Systems Changes Name to Cyrcadia Health

FIRST WARNING SYSTEMS CHANGES NAME TO CYRCADIA HEALTH TO BETTER REFLECT CORE COMPETENCY AND GOALS OF COMPANY Pioneer in Early Cancer Detection Receives $1 Million in Angel Funding Enabling the Final Stages of Clinical Validation Reno, Nev. – Sept. 30, 2014 – First Warning Systems, a pioneer in early cancer detection through measuring abnormal circadian cellular changes throughout the body, announced the company is changing its name to Cyrcadia Health, Inc. to better address the company’s breadth of upcoming product releases. The initial focus will be on wearable early breast cancer screening technology. “Our initial focus will be an ‘Internet of Everthing,’ wearable early breast cancer system which detects abnormal circadian cellular changes over time,” said Rob Royea, president and CEO of Cyrcadia Health. “With our most recent infusion of capital, we are able to take this unique technology into final clinical validation trials in the U.S. starting in November. It is our intention to launch this product into South Asia and Europe in mid-2015 followed by the U.S. after final FDA clinical clearance.” The company’s wearable, smart phone enabled technology, called the iTBraTM, uses a comfortable data collection device placed under a bra to collect 2-12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cellular change, the results of which are transferred through a smart device to a global cancer library and communicated back to the patient and physician. “We have historically raised $1.9 Million in seed monies for the launch of our upcoming technologies” said...

Mammography screening IS being abolished in Switzerland?

By: Bonnie Rush, RT(R)(M)(QM) Did you read that Mammography screening IS being abolished in Switzerland? It may not happen. But there’s continued controversy swirling around the value of early detection and mammography. Naysayers suggest that early detection with screening mammography may not be providing the biggest bang for the medical buck. They may be right about the value of mammography, but let’s make sure they do not forget, we want early detection and we are worth more than a buck – or even two. The concern is that this continued debate may cause insurance companies to throw out the baby (early detection) with the bathwater (mammography). While it is true that some breast cancers cannot be overcome no matter the timing of detection, earlier allows a better outcome in most cases and reduces the impact of treatment. Similar to having a cavity, if caught early enough one does not have to lose the entire tooth. I think the controversy on the value of this “early detection tool” points to the lack of adequate and realistic education about the limitations of mammography and how dense tissue impacts the ability to “see” cancers (white cancer in a white dense tissue background). Even the much-touted newest mammography technology – digital breast tomosynthesis – failed to find the invasive cancer buried in my dense tissue. And guess what – there are lots of me’s around. This includes ALL women when their hormones are the most active and makes mammography of less value in finding cancers and increases the amount of radiation to those “younger” breasts. Thus the generally accepted United States policy to...

BREAST HEALTH AWARENESS AN INTEGRAL PART OF YOUR WELLNESS PROGRAM

By:  Bonnie Rush, RT(R)(M)(QM) Did you read that Mammography screening IS being abolished in Switzerland? It may not happen. But there’s continued controversy swirling around the value of early detection and mammography. Naysayers suggest that early detection with screening mammography may not be providing the biggest bang for the medical buck. They may be right about the value of mammography, but let’s make sure they do not forget, we want early detection and we are worth more than a buck – or even two. The concern is that this continued debate may cause insurance companies to throw out the baby (early detection) with the bathwater (mammography). While it is true that some breast cancers cannot be overcome no matter the timing of detection, earlier allows a better outcome in most cases and reduces the impact of treatment. Similar to having a cavity, if caught early enough one does not have to lose the entire tooth. I think the controversy on the value of this “early detection tool” points to the lack of adequate and realistic education about the limitations of mammography and how dense tissue impacts the ability to “see” cancers (white cancer in a white dense tissue background). Even the much-touted newest mammography technology – digital breast tomosynthesis – failed to find the invasive cancer buried in my dense tissue. And guess what – there are lots of me’s around. This includes ALL women when their hormones are the most active and makes mammography of less value in finding cancers and increases the amount of radiation to those “younger” breasts. Thus the generally accepted United States policy to...